On November 04, 2020, NHS England published an update of the Specialized Services Policy Pipeline (as of October 19, 2020).
There are three types of Work Programmes:
- Clinical commissioning policy work program;
- Specialized commissioning service specification work program;
- Commissioning through evaluation work programs.
Updates were only made in the clinical commissioning policy work program.
Four new Clinical Commissioning Policies were added to the work program, one of them for "Autologous haematopoietic stem cell transplant for refractory coeliac disease"
Five of six new published policies are related to medicines:
- "Cystic fibrosis transmembrane conductance regulator (CFTR for rarer mutations)" (policy statement)
- "Ivacaftor and tezacaftor/ivacaftor for cystic fibrosis: "off-label" use in patients with named rarer mutations" (urgent policy statement)
- "Use of plerixafor for stem cell mobilisation in adults and paediatrics for stem cell mobilisation in adults and paediatrics"
- "Rituximab & Eculizumab for treatment of delayed haemolytic transfusion reaction/post transfusion hyperphaemolysis in patients with sickle cell disease"
- "Vonicog alfa for recombinant manufactured von Willebrand factor for von Willebrand disease"
One proposed policy was rejected - "Omalizumab for treatment of severe sight threatening allergic eye disease in children and young people".
One policy was discontinued - "Plasma Exchange for acute disseminated encephalomyelitis".
No changes were made in paused polices status.
The status of ongoing policies updated as of October 19, 2020.
See the full details here